Development and use of alefacept to treat psoriasis
GG Krueger, KP Callis - Journal of the American Academy of Dermatology, 2003 - Elsevier
Activated memory T cells, expressing CD2, are key components in the pathogenesis of
psoriasis. Alefacept binds to CD2, blocks co-stimulatory signaling, and selectively induces
apotosis of pathogenic T cells. Our objective is to present safety and efficacy results which
lead to the new drug application (NDA) of alefacept for the treatment of psoriasis. We
reviewed the key phase II and III trials in over 1300 patients and found that during treatment
and follow-up of patients receiving 12 weekly intramuscular or intravenous injections of …
psoriasis. Alefacept binds to CD2, blocks co-stimulatory signaling, and selectively induces
apotosis of pathogenic T cells. Our objective is to present safety and efficacy results which
lead to the new drug application (NDA) of alefacept for the treatment of psoriasis. We
reviewed the key phase II and III trials in over 1300 patients and found that during treatment
and follow-up of patients receiving 12 weekly intramuscular or intravenous injections of …